Advertisement

The Scientist

» biotech and immunology

Most Recent

image: All Systems Go

All Systems Go

By | December 1, 2014

Alan Aderem earned his PhD while under house arrest for protesting apartheid in South Africa. His early political involvement has guided his scientific focus, encouraging fellow systems biologists to study immunology and infectious diseases.

0 Comments

image: Bespoke Cell Jackets

Bespoke Cell Jackets

By | December 1, 2014

Scientists make hydrogel coats for individual cells that can be tailored to specific research questions.

0 Comments

image: Incentivizing Breakthroughs

Incentivizing Breakthroughs

By | December 1, 2014

With scientific funding on shaky ground, big-dollar competitions offer a new way for life-science innovators to bring their ideas to fruition.

1 Comment

image: Poor Little Devils

Poor Little Devils

By | November 1, 2014

See the devastating infectious cancer that may drive the Tasmanian Devil to extinction.

0 Comments

image: Epigenetics of Trained Innate Immunity

Epigenetics of Trained Innate Immunity

By | September 25, 2014

Documenting the epigenetic landscape of human innate immune cells reveals pathways essential for training macrophages.

2 Comments

image: Roche Buys Biotech for $8.3B

Roche Buys Biotech for $8.3B

By | August 27, 2014

The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.

0 Comments

image: Biotech Terminates IPO

Biotech Terminates IPO

By | August 15, 2014

The Israeli firm Vascular Biogenics withdrew its initial public offering after six days of trading. 

0 Comments

image: Done with Immunosuppressants

Done with Immunosuppressants

By | July 3, 2014

Adult sickle-cell patients have safely stopped taking their immunosuppressant medication thanks to a new type of blood stem-cell transplant.

1 Comment

image: Protein Clumps Spread Inflammation

Protein Clumps Spread Inflammation

By | June 22, 2014

ASC specks—protein aggregations that drive inflammation—are released from dying immune cells, expanding the reach of a defense response.

1 Comment

image: Merck Snaps Up Biotech for $3.85B

Merck Snaps Up Biotech for $3.85B

By | June 10, 2014

The drug giant will acquire Cambridge, Massachusetts-based Idenix Pharmaceuticals, which is focused on developing treatments for hepatitis C.

0 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Biology Research
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
The Scientist
The Scientist
Advertisement
The Scientist
The Scientist